|
|
 |
|
Viewing report
|
|
|
|
Commercial Perspectives: Vaccines - Nosocomial Pathogens
Datamonitor, Jan 2004, Pages: 146
Introduction
The vaccines sector is undergoing a period of growth, making it a more attractive market to pharmaceutical companies. In addition, changing population demographics, competition and new technologies are further transforming this area. Indeed, novel vaccines are anticipated to provide protection against a much wider spectrum of conditions, including infection by the major nosocomial pathogens.
Scope
Overview of the current vaccine market, describing the key drivers and resistors of growth
Descriptions of key players and new contenders in vaccines sector, detailing their current portfolios and commercial strategies
Highlights
The growth rate for the global vaccines market currently outpaces other infectious diseases sectors with predicted year-on-year growth of 10-12%, equating to a market size of approximately $17 billion in 2010, on a par with antivirals. Datamonitor believes a large proportion of these sales will fall outside the existing four-company oligopoly.
Reasons to Purchase
Gain insight into the current vaccine market, and identify the key players and emerging novel technologies
Identify the companies leading the development of nosocomial vaccines and their strategies and pipeline products
Scope
Characterization of the clinically-significant nosocomial pathogens and information regarding the potential vaccine market size for each
Profiles of pipeline nosocomial vaccines and an evaluation of their market potential and likely impact
Highlights
Within the dominant high-volume pediatric segment, declining birth rates, uncertain market access and intense competition forces vaccine players to consider a range of new product strategies with a varying levels of commercial risk. Examples include monoclonal antibodies, therapeutic vaccines, newer adjuvants and delivery systems.
The niche sector of nosocomial infection vaccines has seen investment by numerous pharmaceutical companies in recent years, with many products in clinical development. Datamonitor predicts that peak global sales of an S. aureus prophylactic vaccine and therapeutic monoclonal antibody could reach $1.8 billion and $2.6 billion respectively.
Reasons to Purchase
Recognize the market potential for nosocomial vaccines
Region: Global
Customers who bought this item also bought
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
The 2009 World Market Forecasts for Imported Butadiene Rubber (BR)
Br Malls Participacoes Sa
Br. Holdings Corporation
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Estonia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Slovakia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Turkey
The 2009 Import and Export Market for Butadiene Rubber (BR) in Uruguay
|
|
|
|
